Inside Diagnostics BJMO publishes new testing guidelines for NSCLC integrating PD-L1 in the biomarker algorithm

 

 

IASLC
IASLC

The September issue of the Belgian Journal of Medical Oncology contains a detailed article on the updated NSCLC testing guidelines. The authors discuss in detail the best position of PD-L1 as a biomarker in the overall panel of tests for stage 3 and stage 4 NSCLC patients. The new algorithm reflects the additional therapeutic choices that have become available for the patient. The article contains very useful information including cytology samples processed to cell blocks can be used for PD-L1 testing if a biopsy or resection sample is not available and the good concordance of the CE-IVD PD-L1 kits based on the SP263, 22C3 and 28.8 antibodies.

The article concludes with very clear recommendations for the clinical practice:

  1. PD-L1 immunohistochemistry reflex testing is recommended for all types of stage III and stage IV non-small cell lung cancer patients.
  2. PD-L1 immunohistochemistry testing for patients with lower stage disease should be discussed locally.
  3. The interpretation of PD-L1 immunohistochemistry should be done by a pathologist, recognised by the Belgian Ministry of Health, who obtained an appropriate training certificate.

Good reading! Free article download

 

Rudy Hovelinck
Diagnostics Manager at AstraZeneca

 

NS ID BE-1676-RD09/2018-LB

Other Inside Diagnostic Articles

About the Author

Rudy Hovelinck

Diagnostics Manager AstraZeneca

rudy.hovelinck@astrazeneca.com

M. +32 (0) 476 22 58

Rudy Hovelinck obtained a scientific degree first in biochemistry at Ghent University and later in Molecular Biology at the ULB. Initially exploring the academic world in diverse fields as genetics, protein chemistry and virology, he soon realised that bridging scientific knowledge to the medical world was a more meaningful way of spending his professional life. This journey started in the field of pathology biomarker testing, introducing HER2 IHC and ISH testing for patient therapy selection and continued in the field of molecular oncology. Today at AstraZeneca he works as a diagnostics manager. In this role he is passionately contributing to the successful introduction of novel biomarkers and support current testing strategies for patient selection. In his own time he enjoys travelling with his family exploring the world and spending time close to nature. Specialties: Oncology, Anatomic Pathology, Biomarker Development, Medical Devices.